We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+27.74%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.71B
AUM Growth
+$107M
Cap. Flow
-$182M
Cap. Flow %
-10.62%
Top 10 Hldgs %
37.71%
Holding
102
New
9
Increased
24
Reduced
36
Closed
9

Top Buys

Rank Stock Value
1
HTFL
Heartflow Inc
HTFL
+$8.04M
2
CDTX
Cidara Therapeutics
CDTX
+$7.36M
3
LENZ
LENZ Therapeutics
LENZ
+$5.6M
4
TVTX icon
Travere Therapeutics
TVTX
+$4.82M
5
BBIO icon
BridgeBio Pharma
BBIO
+$4.15M

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$30.4M
2
BPMC
Blueprint Medicines
BPMC
+$23.8M
3
ARGX icon
argenx
ARGX
+$21.8M
4
INSM icon
Insmed
INSM
+$17.2M
5
UNH icon
UnitedHealth
UNH
+$15.8M

Sector Composition

Rank Sector Weight
1 Healthcare 98.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
76
DELISTED
Apellis Pharmaceuticals
APLS
$2.08M 0.12%
92,000
+7,700
+9% +$180K
NGNE icon
77
Neurogene
NGNE
$671M
$1.81M 0.11%
104,339
– –
KRRO icon
78
Korro Bio
KRRO
$201M
$1.71M 0.1%
35,719
– –
CNTA
79
DELISTED
Centessa Pharmaceuticals
CNTA
$1.68M 0.1%
+69,240
New +$1.23M
CATX icon
80
Perspective Therapeutics
CATX
$351M
$1.52M 0.09%
444,383
– –
APLT
81
DELISTED
Applied Therapeutics
APLT
$1.26M 0.07%
2,075,991
– –
MRSN
82
DELISTED
Mersana Therapeutics
MRSN
$1.18M 0.07%
152,586
-1
-0% -$8
IMVT icon
83
Immunovant
IMVT
$8.17B
$1.18M 0.07%
72,965
-148,535
-67% -$2.4M
NAMS icon
84
CALL
NewAmsterdam Pharma
NAMS
$3.35B
$899K 0.05%
+31,600
New +$757K
EYPT icon
85
EyePoint Inc
EYPT
$1.08B
$451K 0.03%
+31,655
New +$364K
CRL icon
86
Charles River Laboratories
CRL
$13.3B
$422K 0.02%
2,700
– –
PCVX icon
87
Vaxcyte
PCVX
$8.81B
$400K 0.02%
11,100
– –
NVAX icon
88
Novavax
NVAX
$1.29B
$390K 0.02%
45,000
-8,900
-17% -$69.3K
PRTA icon
89
Prothena Corp
PRTA
$468M
$248K 0.01%
25,398
-467,203
-95% -$3.59M
MLTX icon
90
MoonLake Immunotherapeutics
MLTX
$1.36B
$202K 0.01%
+28,200
New +$1.47M
NUVB.WS
91
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$27.1K ﹤0.01%
134,028
– –
CGEN icon
92
Compugen
CGEN
$223M
$19.7K ﹤0.01%
13,430
-976,560
-99% -$1.45M
ADAP
93
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-2,483,468
Closed -$595K
BPMC
94
DELISTED
Blueprint Medicines
BPMC
– –
-185,500
Closed -$23.8M
CGEM icon
95
Cullinan Oncology
CGEM
$1.23B
– –
-668,233
Closed -$5.03M
ETNB
96
DELISTED
89bio
ETNB
– –
-40,000
Closed -$393K
LUNG icon
97
Pulmonx
LUNG
$97.9M
– –
-651,100
Closed -$1.69M
NUVL
98
DELISTED
Nuvalent
NUVL
– –
-93,328
Closed -$7.12M
OSCR icon
99
Oscar Health
OSCR
$8.63B
– –
-700,000
Closed -$15M
SRPT icon
100
Sarepta Therapeutics
SRPT
$1.88B
– –
-68,600
Closed -$1.17M
1 2 3
4
5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Rock Springs Capital Management held 102 positions worth $1.71B, up 6.7% from $1.6B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Rock Springs Capital Management withdrew a net $182M in Q3 2025, closing 9 positions and reducing 36 holdings. Its most notable exit was Blueprint Medicines, an estimated $23.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier.

Against the trend, Rock Springs Capital Management opened a new position in Heartflow Inc worth $8.41M.

  • Rock Springs Capital Management's largest Q3 2025 buy was Heartflow Inc: 250,000 shares worth $8.41M.
  • Rock Springs Capital Management added most to Cidara Therapeutics in Q3 2025, an estimated $7.36M increase.
  • Rock Springs Capital Management's biggest Q3 2025 reduction was Merus, cutting an estimated $30.4M.
  • Rock Springs Capital Management fully exited Blueprint Medicines in Q3 2025, selling an estimated $23.8M.
  • Rock Springs Capital Management's ten largest holdings make up 38% of its $1.71B portfolio in Q3 2025.
  • Rock Springs Capital Management opened 9 new positions and closed 9 in Q3 2025.
  • Rock Springs Capital Management's portfolio value rose 6.7% quarter-over-quarter to $1.71B.

Based on Rock Springs Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.